The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO 2026 | IMbrave251: final analysis of aezolizumab and TKIs in second-line HCC
Stephen Lam Chan, MD, FRCP, Chinese University of Hong Kong, Hong Kong, China, presents final analysis results from the Phase III IMbrave251 trial (NCT04770896) of atezolizumab and lenvatinib or sorafenib versus lenvatinib or sorafenib alone in patients with locally advanced or metastatic hepatocellular carcinoma (LA/mHCC) previously treated with atezolizumab and bevacizumab. Although the primary overall survival endpoint was not met, results established a new benchmark for second-line treatment in this setting, with a manageable safety profile observed with the combination. This interview took place during the 2026 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
For the 251 study, it’s also an RCT looking at those patients who have developed PD to the previous atezolizumab and bevacizumab. And they randomized those patients to atezolizumab plus the TKI, either lapatinib or sorafenib, while the control arm was the TKI alone, the lapatinib, or sorafenib. The primary endpoint is the overall survival, and the studies showed that the median overall survival was not improved, or there’s no difference between the arm A and the arm B, i...
For the 251 study, it’s also an RCT looking at those patients who have developed PD to the previous atezolizumab and bevacizumab. And they randomized those patients to atezolizumab plus the TKI, either lapatinib or sorafenib, while the control arm was the TKI alone, the lapatinib, or sorafenib. The primary endpoint is the overall survival, and the studies showed that the median overall survival was not improved, or there’s no difference between the arm A and the arm B, i.e., the continuation of the atezolizumab after the previous atezolizumab and bevacizumab treatment did not improve the outcome when combined with the TKI.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
